Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.
Zhou C, Li C, Gong GZ, Wang S, Zhang JM, Xu DZ, Guo LM, Ren H, Xu M, Xie Q, Pan C, Xu J, Hu Z, Geng S, Zhou X, Wang X, Zhou X, Mi H, Zhao G, Yu W, Wen YM, Huang L, Wang XY, Wang B. Zhou C, et al. Among authors: xu m, xu dz, xu j. Hum Vaccin Immunother. 2017 Sep 2;13(9):1989-1996. doi: 10.1080/21645515.2017.1335840. Epub 2017 Jun 30. Hum Vaccin Immunother. 2017. PMID: 28665747 Free PMC article.
Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.
Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Xu J, Yuan ZH, Wang B, Zhao K, Wen YM; YIC Efficacy Trial Study Team. Xu DZ, et al. Among authors: xu m, xu c, xu j. J Hepatol. 2013 Sep;59(3):450-6. doi: 10.1016/j.jhep.2013.05.003. Epub 2013 May 11. J Hepatol. 2013. PMID: 23669281 Clinical Trial.
Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results.
Liang X, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J, Chen C, Mao Q, Zhao W, Ren H, Tan D, Niu J, Chen S, Pan C, Tang H, Wang H, Mao Y, Jia J, Ning Q, Xu M, Wu S, Li J, Zhang X, Zhang W, Xiong C, Hou J. Liang X, et al. Among authors: xu m. Hepatol Int. 2019 May;13(3):260-269. doi: 10.1007/s12072-019-09943-6. Epub 2019 Apr 11. Hepatol Int. 2019. PMID: 30977033 Free PMC article. Clinical Trial.
Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R, Peng J, Xie Q, Tan D, Xu M, Niu J, Wang H, Ren H, Chen X, Wang M, Sheng J, Tang H, Bai X, Wu Y, Zhou B, Sun J, Hou J; Chronic Hepatitis B Study Consortium. Fan R, et al. Among authors: xu m. J Infect Dis. 2020 Jul 23;222(4):611-618. doi: 10.1093/infdis/jiaa136. J Infect Dis. 2020. PMID: 32211776 Clinical Trial.
Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.
Yu R, Tan D, Ning Q, Niu J, Bai X, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J, Xie Q, Sun J. Yu R, et al. Among authors: xu m. Hepatol Res. 2018 Feb;48(3):E213-E221. doi: 10.1111/hepr.12972. Epub 2017 Oct 4. Hepatol Res. 2018. PMID: 28834607
Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy.
Fan R, Zhou B, Xu M, Tan D, Niu J, Wang H, Ren H, Chen X, Wang M, Ning Q, Shi G, Sheng J, Tang H, Bai X, Liu S, Lu F, Peng J, Sun J, Xie Q, Hou J; Chronic Hepatitis B Study Consortium. Fan R, et al. Among authors: xu m. Clin Gastroenterol Hepatol. 2020 Mar;18(3):719-727.e7. doi: 10.1016/j.cgh.2019.07.046. Epub 2019 Jul 27. Clin Gastroenterol Hepatol. 2020. PMID: 31362119 Free article. Clinical Trial.
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. Sun J, et al. Among authors: xu m. Hepatology. 2014 Apr;59(4):1283-92. doi: 10.1002/hep.26885. Epub 2014 Feb 28. Hepatology. 2014. PMID: 24382690 Clinical Trial.
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.
Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J; Chronic Hepatitis B Study Consortium. Fan R, et al. Among authors: xu m. Gut. 2016 Feb;65(2):313-20. doi: 10.1136/gutjnl-2014-308546. Epub 2015 Jan 13. Gut. 2016. PMID: 25586058 Free PMC article. Clinical Trial.
22,182 results
You have reached the last available page of results. Please see the User Guide for more information.